RecruitingNCT06881238

Impact of Hepatitis B Virus on Inflammatory Bowel Disease

The Impact of Hepatitis B Virus Infection on the Clinical Course of Inflammatory Bowel Disease in Egyptian Patients


Sponsor

Tanta University

Enrollment

162 participants

Start Date

Dec 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

The goal of this observational retrospective study is to assess the impact of hepatitis B virus (HBV) infection on the clinical course and outcomes of inflammatory bowel disease (IBD) in Egyptian patients. Researchers will compare the IBD extent, location, severity, and behavior between IBD patients with and without HBV infection. Participants will be subjected to history-taking (history of hospital admission and disease flare, surgical history, medication history, follow-up duration, and mortality), clinical examination, laboratory investigations, abdominal ultrasonography, and endoscopic examination.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Male or female patients older than 18 years.
  • Patients with IBD are diagnosed by clinical, radiological, endoscopic, and histological criteria.

Exclusion Criteria2

  • Patients aged < 18 years
  • Unwilling to participate in our study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERHistory of IBD course and outcome in HBV patients

Full history taking including: * Personal history (name, age, sex, occupation, residence, and marital state). * Complaint. * Age at diagnosis of IBD. * Medication history. * History of hospital admissions and disease flares. * Disease extent, location, and behavior. (Montreal classification, Truelove-Witts severity index). * Surgical history (intestinal resection in CD patients and total proctocolectomy in UC patients). * Follow up duration and mortality. * Data of endoscopic examination * Data of laboratory investigations (complete blood picture, HBV serology, liver and kidney function tests, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP)).


Locations(1)

Tanta University Hospitals

Tanta, Gharbyea, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06881238


Related Trials